Pragma Bio

Pragma Bio is a biotechnology company that mines microbiome drugs to treat cancer and autoimmune disease.

The company employs its proprietary methods in genomic sequencing, artificial intelligence, and synthetic biology to discover biomarkers and therapeutics for challenging immunologic disorders. It offers a platform that aims to aggregate public and private data in order to generate a microbiome database and leverages analytical processes to discover connections between distinct and biologically related data in order to increase statistical power and drive discovery. In addition, the platform can be used to identify novel biomarkers to risk-stratify patients and predict clinical outcomes.

It was co-founded by Peter McCaffrey, Kovi Bessoff, Ayin Vala, and Kareem Barghouti in Millbrae, California in 2018.

Pragma Bio headquartered in United States, North America, operates in the Biotechnology, Predictive Analytics, Therapeutics sector. The company focuses on Biotechnology and has secured $1.2B in funding across 84 round(s). With a team of 11-50 employees, Pragma Bio is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Pragma Bio, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.